ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly To Invest In Irish Biopharma

by Rick Mullin
March 5, 2012 | APPEARED IN VOLUME 90, ISSUE 10

[+]Enlarge
Credit: Eli Lilly & Co.
Aerial view of the Kinsale site.
09010-buscon-lillyfieldcxd.jpg
Credit: Eli Lilly & Co.
Aerial view of the Kinsale site.

Eli Lilly & Co. plans to invest about $444 million to expand biopharmaceutical manufacturing capacity in Kinsale, near Cork, Ireland. Lilly opened its first biopharmaceutical plant at the site in 2010 following a $400 million investment. The new facility, which is expected to employ 200 workers, is due to come on-line in 2015. The Kinsale site, which opened in 1981, has manufactured drugs such as the antidepressant Prozac and the osteoporosis treatment Evista. With Lilly’s sale of its Tippecanoe Laboratories site in Lafayette, Ind., to Evonik Industries, Kinsale has become a key location for product commercialization as well.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment